163258-24-0Relevant academic research and scientific papers
Indolyne experimental and computational studies: Synthetic applications and origins of selectivities of nucleophilic additions
Im, G-Yoon J.,Bronner, Sarah M.,Goetz, Adam E.,Paton, Robert S.,Cheong, Paul H.-Y.,Houk,Garg, Neil K.
supporting information; experimental part, p. 17933 - 17944 (2011/02/26)
Efficient syntheses of 4,5-, 5,6-, and 6,7-indolyne precursors beginning from commercially available hydroxyindole derivatives are reported. The synthetic routes are versatile and allow access to indolyne precursors that remain unsubstituted on the pyrrole ring. Indolynes can be generated under mild fluoride-mediated conditions, trapped by a variety of nucleophilic reagents, and used to access a number of novel substituted indoles. Nucleophilic addition reactions to indolynes proceed with varying degrees of regioselectivity; distortion energies control regioselectivity and provide a simple model to predict the regioselectivity in the nucleophilic additions to indolynes and other unsymmetrical arynes. This model has led to the design of a substituted 4,5-indolyne that exhibits enhanced nucleophilic regioselectivity.
Copper(I)-2-(2′-pyridyl)benzimidazole catalyzed N-arylation of indoles
Haneda, Satoshi,Adachi, Yusuke,Hayashi, Masahiko
supporting information; experimental part, p. 10459 - 10462 (2010/02/28)
CuI-2-(2′-pyridyl)benzimidazole catalyst system can serve efficiently to promote N-arylation of various indoles to afford the N-arylated indoles. The bidentate ligand, 2-(2′-pyridyl)benzimidazole was proved superior to monodentate nitrogen-based ligands and well-known bidentate ligands such as 2,2′-bipyridyl and 1,10-phenanthroline.
SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
-
Page column 128; 129, (2010/02/06)
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
Tryptamine analogues as 5-ht1-like agonists
-
, (2008/06/13)
A compound of structure (I), in which A1 is O, S(O)n in which n is 0, 1 or 2, NR, CH2, or CH(OH); A2 is a bond or CH2 ; or A1 A2 is CH=CH; R is hydrogen or C1-4 alkyl;
